Spots Global Cancer Trial Database for Dose Finding Study of GH35 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dose Finding Study of GH35 in Patients With Advanced Solid Tumors
Official Title: A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Antitumor Activity of GH35 in Patients With Advanced Solid Tumors With KRAS Mutation
Study ID: NCT05010694
Interventions
Study Description
Brief Summary: Evaluate the safety and tolerability of GH35 in patients with KRAS mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in patients with KRAS mutant advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
Shanghai Chest Hospital, Shanghai, Shanghai, China
Contact Details
Name: Baohui Han, Professor
Affiliation: Shanghai Chest Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
